Evidence map›Paper›PMID 41067563›Full record

ArticleAntiviral research2025

Ciclopirox suppresses poxvirus replication by targeting iron metabolism.

Anil Pant, Djamal Brahim Belhaouari, Lara Dsouza, D M Nirosh Udayanga, Zhengqiang Wang, Zhilong Yang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Anil PantDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Djamal Brahim BelhaouariDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA.
Lara DsouzaDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA.
D M Nirosh UdayangaCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
Zhengqiang WangCenter for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN, 55455, USA.
Zhilong YangDepartment of Veterinary Pathobiology, College of Veterinary Medicine & Biomedical Sciences, Texas A&M University, College Station, TX, USA. Electronic address: zhilongyang@tamu.edu.

Funding

Development of novel antivirals against mpox (monkeypox) virusR01AI183580 · NIAID · UNIVERSITY OF MINNESOTA · PI Zhengqiang Wang, Zhilong Yang · 2024 to 2026
$2.3M
NIAID NIH HHS R01 AI183580
6 · The paper itself

Abstract

Poxviruses remain a significant global health concern, necessitating the development of novel antiviral strategies. Through high-throughput screening, we previously identified ciclopirox (CPX), an FDA-approved antifungal, as a hit that inhibits vaccinia virus (VACV) replication. Here, we further characterized its antiviral activity and mechanism of action using human primary fibroblasts. CPX significantly reduced VACV titers without reducing host cell viability, with an EC

Indexed as

Antiviral AgentsCiclopiroxIronPoxviridaeVaccinia virusVirus ReplicationAnimalsCells, CulturedFibroblastsHumansMiceAntiviral AgentsCiclopiroxIronAntiviralCiclopiroxIron metabolismMonkeypox virusMpoxPoxviruses

Identifiers

PMID41067563
PMCPMC12714420

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.